Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to 6403.7%.

  • Seres Therapeutics' EBITDA Margin changed N/A to 6403.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 25706.84%, marking a year-over-year increase of 140978500.0%. This contributed to the annual value of 90.02% for FY2023, which is 34188100.0% up from last year.
  • Latest data reveals that Seres Therapeutics reported EBITDA Margin of 6403.7% as of Q3 2025.
  • In the past 5 years, Seres Therapeutics' EBITDA Margin registered a high of 53.83% during Q3 2021, and its lowest value of 64450.0% during Q4 2023.
  • Its 4-year average for EBITDA Margin is 9228.92%, with a median of 3803.01% in 2022.
  • Over the last 5 years, Seres Therapeutics' EBITDA Margin had its largest YoY gain of 53637800bps in 2023, and its largest YoY loss of -574048700bps in 2023.
  • Seres Therapeutics' EBITDA Margin (Quarter) stood at 693.42% in 2021, then crashed by -916bps to 7045.13% in 2022, then tumbled by -815bps to 64450.0% in 2023, then surged by 90bps to 6403.7% in 2025.
  • Its EBITDA Margin stands at 6403.7% for Q3 2025, versus 64450.0% for Q4 2023 and 15436.45% for Q3 2023.